RepliCel Life Sciences, Inc.
18.10.2021 15:09:29 CEST | ACCESS Newswire | Press release
After several unsuccessful attempts to settle the dispute, RepliCel has filed an arbitration claim seeking Shiseido's full compliance with the agreement or return of the license and all collaboration data and innovations related to its cell therapy treatment for male and female pattern hair loss.
VANCOUVER, BC / ACCESSWIRE / October 18, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, announced today it has retained Aceris Law LLC, a law firm specialized in international arbitration, to pursue the resolution of its disagreement with Shiseido Company Limited ("Shiseido").
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.The Company further announced that its legal counsel has now filed a Notice of Arbitration and provided a copy to Shiseido in accordance with the International Center for Dispute Resolution (ICDR) Rules, which are the arbitration rules that govern all disagreements between the parties.
The dispute between Shiseido and RepliCel is related to a license for Asia, acquired by Shiseido, to RepliCel's cell therapy technology for androgenetic alopecia, which is the leading cause of male and female pattern hair loss.
In accordance with the ICDR rules, once an arbitrator is selected and the parties have filed their claims and responses, the arbitrator will accept evidence and arguments in support of a ruling on whether or not either party materially breached the license agreement and what relief should be awarded as a result of the ruling including enforcement of the license agreement, return of the license, and/or payment of damages including the equivalent of all reasonably expected future milestone and royalty payments.
Legal counsel for RepliCel issued several demand letters to Shiseido to comply with the terms of its license agreement which RepliCel alleges Shiseido has now breached which, if not cured, could result in the return of the license to RepliCel for re-licensing to other partners in Asia.
About RepliCel Life Sciences
RepliCel is a regenerative medicine company focused on developing cell therapies for aesthetic and orthopedic conditions affecting what the Company believes is approximately one in three people in industrialized nations, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. These conditions, often associated with aging, are caused by a deficit of healthy cells required for normal tissue healing and function. These cell therapy product candidates are based on RepliCel's innovative technology, utilizing cell populations isolated from a patient's healthy hair follicles.
The Company's product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is exclusively licensed in Asia to Shiseido Company Limited. RepliCel maintains the rights to RCH-01 for the rest of the world. RCT-01 and RCS-01 are exclusively licensed in Greater China to YOFOTO (China) Health Company. RepliCel and YOFOTO are currently co-developing these products in China. RepliCel maintains the rights to these products outside of Greater China.
RepliCel has also developed a proprietary injection device, RCI-02, and related consumables, which is expected to improve the administration of its cell therapy products and certain other injectables. YOFOTO has exclusively licensed the commercial rights for the RCI-02 device and consumables in Greater China for dermatology applications and is expected to first launch the product in Hong Kong upon it being approved for market launch in either the United States or Europe. Please visit www.replicel.com for additional information.
Notable Facts:
- RepliCel's three cell therapy products have now been tested in over 100 patients in four countries on three continents.
- RepliCel now has key strategic partners in the United States, China, and Japan each of which are now investing heavily in the further clinical testing and development of RepliCel's products for their markets. Data from each of the clinical programs will strengthen the product development initiatives for RepliCel and its other partners worldwide.
For more information, please contact:
Lee Buckler, CEO and President
604-248-8693
info@replicel.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: RepliCel Life Sciences, Inc.
View source version on accesswire.com:
https://www.accesswire.com/668473/RepliCel-Files-Notice-of-Arbitration-against-Shiseido-Company-to-Resolve-its-License-Agreement-Dispute-Regarding-its-Androgenetic-Alopecia-Cell-Therapy
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
GA-ASI's UK and Japan MQ-9B Programs Are Honored With Excellence Awards from Aviation Week24.3.2026 20:00:00 CET | Press release
GA-ASI Wins 2 of the 9 Awards Presented SAN DIEGO, CA / ACCESS Newswire / March 24, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) was named the winner of two awards during Aviation Week's 21st annual Program Excellence Awards last week. GA-ASI's United Kingdom (UK) Protector Program was given the Special Projects Award, while its Japan COCO (Company-Owned, Company-Operated) Program won in the category of OEM System Sustainment. "We're excited that these two important MQ-9B international programs have been recognized by Aviation Week," said GA-ASI CEO Linden Blue. "We're fortunate to have an incredible team of employees whose dedication and commitment to our customers is truly remarkable." MQ-9B is GA-ASI's most advanced Remotely Piloted Aircraft (RPA) system and includes the SkyGuardian® and SeaGuardian® models, as well as the UK's Protector RG Mk1. In 2025, GA-ASI achieved the first-ever Military Type Certificate (MTC) for the Royal Air Force's (RAF) Protector RG Mk1, pas
Professional Services Firms Bet Big on AI but Skills Gaps Are Holding Them Back, General Assembly Survey Finds24.3.2026 14:00:00 CET | Press release
Most firms have had to abandon at least one AI initiative due to a lack of skills in the past year NEW YORK, NY / ACCESS Newswire / March 24, 2026 / Most professional services firms (61%) have had to abandon at least one AI initiative in the past year due to a lack of internal skills, with more than a third (35%) abandoning multiple initiatives, according to new research from General Assembly, the global leader in practical AI skills training and an LHH company. "Professional services firms face a capability paradox," said Ash Khanna, Head of Professional Services at General Assembly. "AI can accelerate output, but it can't replace the judgment that comes from doing the hard work. We're seeing junior talent generate recommendations faster than ever, but struggle to defend the reasoning behind them. Firms must invest in the durable human skills that make AI output credible and defensible. Upskilling can't be an afterthought; it has to be as central to a firm's AI strategy as the technol
Innodata Announces Date of Annual Shareholder Meeting24.3.2026 13:30:00 CET | Press release
NEW YORK, NY / ACCESS Newswire / March 24, 2026 / INNODATA INC. (Nasdaq:INOD) today announced that its 2026 annual meeting of shareholders is scheduled for Thursday, June 4, 2026, at 5:00 PM eastern time. The meeting will be held virtually. Shareholders of record as of the close of business on April 8, 2026 will be eligible to vote at the annual meeting. About Innodata Innodata (Nasdaq: INOD) is a global data engineering company. We believe that data and Artificial Intelligence (AI) are inextricably linked. Our mission is to enable the responsible advancement of artificial intelligence by providing the data, evaluation frameworks, and human expertise required to build AI systems that can be trusted at scale. We provide a range of transferable solutions, platforms, and services for Generative AI / AI builders and adopters. In every relationship, we honor our 36+ year legacy delivering the highest quality data and outstanding outcomes for our customers. Visit www.innodata.com to learn mo
USPA Global and ESPN Expand Relationship with Chris Fowler for 2026 High-Goal Polo Championships24.3.2026 12:00:00 CET | Press release
USPA Gold Cup and U.S. Open Polo Championship Finals to Air on ESPN2 WEST PALM BEACH, FL / ACCESS Newswire / March 24, 2026 / Global Polo, the entertainment subsidiary of USPA Global, continues its historic relationship with ESPN to showcase the sport of polo, which has expanded its reach to millions of households worldwide. The landmark relationship includes legendary ESPN commentator Chris Fowler hosting the USPA Gold Cup® Final on Mar. 29 for the first time, and the U.S. Open Polo Championship® Final on Apr. 26 for the second year, at the USPA National Polo Center in Palm Beach County, Florida, alongside veteran broadcasters Kenny Rice and Polo Hall-of-Famer Adam Snow.Legendary ESPN Commentator, Chris Fowler, at the USPA National Polo Center in Palm Beach County, Florida Photo Credit: Alex Pacheco "I've had the privilege of covering some of the most iconic events in sports, and what continues to draw me back to the sport of polo is the unique partnership between the polo player and
IXOPAY and Zip US Introduce Unified Trust Layer Framework to Help Merchants Reduce Risk in Agentic Commerce24.3.2026 11:00:00 CET | Press release
Open, Collaborative Initiative to Establish Identity, Preserve Intent, and Make Trust Measurable in AI-Initiated Commerce LEHI, UT AND NEW YORK, NY / ACCESS Newswire / March 24, 2026 / IXOPAY, the enterprise-grade global payment infrastructure platform built for the era of agentic commerce, and Zip, the digital financial services company offering innovative, people-centred products, today announced a joint initiative to define a Unified Trust Layer - an open industry framework designed to address emerging trust and liability challenges in agent-initiated commerce and payments. Agentic commerce introduces a structural shift in payments. Traditional infrastructure was built around a four-party risk model - consumer, merchant, issuing bank, and acquiring bank - with the assumption that a human initiated the transaction. As AI agents begin acting autonomously, that model no longer holds. Payment systems were not designed to consistently preserve identity, intent, and context in a machine-v
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom